Intriguingly, temozolomide (TMZ), a standard first-line drug for malignant glioma, has also been found to have therapeutic potential for controlling proliferation, invasion of malignant glioma by inhibiting AQP4 expression through activation of p38 signal transduction pathway [12, 87]. Here, AQP4 is linked to malignant glioma.